LOX-1, OxLDL, and Atherosclerosis

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Modified lipoproteins</td><td align="center">Other ligands</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">OxLDL (copper-oxidized LDL)</td><td align="center">Apoptotic cells</td></tr><tr><td align="left">15-Lipoxygenase-oxidized LDL</td><td align="center">Activated platelets</td></tr><tr><td align="left">15-Lipoxygenase-oxidized HDL<sub>3</sub></td><td align="center">Advanced glycation end-products (AGEs)</td></tr><tr><td align="left">Glycoxidized LDL</td><td align="center"> </td></tr><tr><td align="left">Delipidated OxLDL</td><td align="center"> </td></tr><tr><td align="left">HOCl-modified HDL</td><td align="center"> </td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Mediators of Inflammation

tab2

Table 2

Table 2: LOX-1, OxLDL, and Atherosclerosis 